37 results about "Alveolus pulmonis" patented technology

The present invention relates to compositions and methods for generating populations of tissue precursor cells from pluripotent cells, and preferably induction of stem cells into definitive endoderm to generate anterior foregut endoderm from pluripotent cells. The anterior foregut endoderm cells can then be differentiated into an alveolar epithelial type II cell.

The invention discloses a method for separating and cultivating II-type epithelial cells of people alveolus pulmonis. By using pancreatin joint elastase to digest and separate, the II-type epithelial cells of people alveolus pelmonis are obtained through filtering, differential adhension, density gradient centrifugation and the separation and purification of Anti-CD 14 magnetic beads. The invention establishes a set of method of separating, cultivating and identifying II-type epithelial cells of people alveolus pulmonis, and the maintaining situation of the biological characteristics of the cells cultivated by the method is assessed. The capacity of obtaining II-type epithelial cells of people alveolus pulmonis with high purity through the cultivating method is certified, moreover, the biological characteristics of cells can be enduringly maintained, and the method provides possibilities for further deep research of the proliferation, differentiation, liquid transferring and synthetizing secretion of II-type epithelial cells of alveolus pulmonis as well as the functional changes of II-type epithelial cells of alveolus pulmonis in the cases of pathophysiology, such as lung injury, lung repair.

The invention discloses a primer group for detecting respiratory tract microorganisms based on a nanopore sequencing method. The nucleotide sequences of the primer group are as shown in SEQ ID NO:1-20. The microorganisms are streptococcus pneumoniae, staphylococcus aureus (resisting to methicillin), klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, stenotrophomonas maltophilia, candida albicans, haemophilus influenzae, legionella pneumophila, enterococcus faecium, chlamydia psittaci, cryptococcus gattii, aspergillus fumigatus and pneumocystis jiroveci. According to the invention, sequencing optimization is carried out on different types of samples of the respiratory tract microorganisms, so that the detection method, the kit and the like are suitable for various typesof respiratory tract samples; and a targeted amplification method is adopted, so that the detection requirements of sputum, alveolar lavage and other sample types can be met. In addition, parallel sequencing can be performed, so that the flux of the detected samples is increased, the sequencing time is shortened, and the contradiction between the flux of detected pathogenic species and the cost and time is further relieved.

The invention discloses a lung tissue model for biotoxicity detection and a biotoxicity detection method. The lung tissue model comprises a trachea, a blood vessel and an alveolus pulmonis unit, wherein an air passage is defined in the trachea, and an air inlet and an air outlet, which are communicated with the air passage respectively are formed at two ends of the trachea; a blood passage is defined inside the blood vessel, and a liquid inlet and a liquid outlet which are communicated with the blood passage respectively are formed at the two ends of the blood vessel, a cavity is defined in the alveolus pulmonis unit, an elastic ventilate membrane is formed on the wall of the alveolus pulmonis unit, the alveolus pulmonis unit is arranged in the blood passage, and the cavity is communicated with the air passage. By adopting the lung tissue model, an air exchanging function and a breathing strain effect of the lung blood in the body can be simulated; through planting cells in the alveolus pulmonis unit, the structure and function of the alveolus pulmonis unit in a body and inflammation reaction of immune cells can be simulated in the subsequent culture process.

The invention discloses an application of platycodon grandiflorum polysaccharide in antagonizing fumonisin B1-induced apoptosis through autophagy. It has been discovered that the toxic effect of FB1 on alveolar macrophages is mainly reflected in induction of apoptosis. The platycodon grandiflorum polysaccharide induces the autophagy through two signal pathways, namely PI3K / Akt / mTOR and MEK / ERK, soas to antagonize FB1-induced alveolar macrophages apoptosis through the autophagy and achieve the protective effect on the alveolar macrophages. According to the application, a regulatory mechanism for interference of the platycodon grandiflorum polysaccharide between the alveolar macrophages apoptosis and the autophagy is illustrated, and a theoretical basis is provided for development of drugsfor treating corresponding diseases.

The invention discloses a lung benefiting pill with 25 ingredients having the function of being homology of medicine and food. The composition of the lung benefiting pill comprises sea buckthorn, radix pseudostellariae, polyporus umbellatus, platycodon grandiflorum, stir-baked rhizoma dioscoreae, milk steamed poria cocos, longan aril, north astragalus, baked perilla seed, baked semen raphani, baked semen brassicae, radix glehniae, radix salviae miltiorrhizae, spina date seed, gecko tails, cordyceps sinensis, almonds, fructus schisandrae, linden honey, salted alisma orientalis, atractylodes macrocephala koidz baked with bran, angelica sinensis, milk steamed polygonatum kingianum, radix ophiopogonis, raw lily and the like. The lung benefiting pill is advantageous to guarantee normal ventilation of alveolus pulmonis and relieves organism anaerobic condition. Due to the fact that the permeability of lung blood capillary is improved, gas exchange is facilitated, and the symptoms of dyspnea and coughing with expectoration are relieved. Weak people with dyspnea and chronic cough generally has the abnormal phenomenon of hemorheology, synchronic treating of phlegm and blood stasis can solve the root cause of sputum and the root cause of blood stasis, bronchospasm can be relieved, discharging of sputum is promoted, cohesive force of red blood cells can be relieved, the blood viscosity is lowered, the hyperviscosity of the weak patients with dyspnea and chronic cough can be relieved, the cardio-pulmonary function of the patients can be improved, and therefore, the lung benefiting pill has good effect on treatment of the patients of this kind.

The invention discloses a medicine for treating pig pneumonia. The medicine is prepared from the following components in parts by weight: 16-38 parts of rhizoma decumbentis, 16-38 parts of spina gleditsiae, 16-38 parts of wild chrysanthemum flowers, 16-38 parts of viola, 16-38 parts of scutellaria baicalensis, 16-38 parts of platycodon grandiflorum, 16-38 parts of charred fructus crataegi, 16-38 parts of brown malts, 16-38 parts of prepared liquorice roots, 28-55 parts of radix angelicae dahuricae, 28-55 parts of akebia stems, 28-55 parts of tetrapanax papyriferus, 28-55 parts of radix paeoniae rubra, 28-55 parts of fructus trichosanthis, 28-55 parts of abrus herb, 28-55 parts of longhairy antenoron herb and 28-55 parts of plantain herb. The medicine can promote blood of pig lungs to flow and dredge bronchus, so that previous elasticity of alveolus pulmonis is recovered and the pig pneumonia can be effectively and rapidly treated; and the medicine is safe and has no toxic or side effect and no residues.

The invention discloses a healthy porcine alveolar macrophage cell line and a construction method and application. The collection number of the healthy porcine alveolar macrophage cell line is CGMCC No: 21498. According to the healthy porcine alveolar macrophage cell line, the 100% healthy porcine alveolar macrophage cell line is screened by adopting a special cell culture solution in combination with a natural domestication selection method, and the healthy porcine alveolar macrophage cell line can be applied to cell culture of viruses, research, development and production of live vaccines and inactivated vaccines and preparation of bioactive substances secreted by M1 and M2 macrophages after induced polarization, and the bioactive substances are used for cancer treatment, inflammation diminishing and the like. According to the invention, the healthy porcine alveolar macrophage cell line is cultured for the first time, any carcinogenic substances such as lentivirus transformation or plasmid transfection are not adopted in the construction method of the invention, and the constructed healthy porcine alveolar macrophage cell line keeps the characteristics of primary porcine alveolar macrophages.

The invention belongs to the field of medical science, and provides a method which is used for preparing a silicosis cell model from a molecular level, is simple, and can accurately represent pulmonary fibrosis in vivo. The method comprises the specific steps: adopting silicious dust to stimulate alveolar macrophages cultured to a stationary period, after 24 h, collecting a supernatant, filtering, and removing bacteria; and adding the silicious dust and the alveolar macrophage supernatant into lung adenocarcinoma cells A549 cultured to a stationary period, jointly incubating lung epithelial cells with the two substances, and completing establishment of the silicosis cell model.

The invention relates to a method of treating lung branching malformation in a subject by administering to the subject a pharmaceutically effective amount of a retinoic acid receptor (RAR) retinoid. The invention also relates to a method of increasing alveoli in a subject by administering a pharmaceutically effective amount of a retinoic acid receptor (RAR) antagonist. The invention further relates to a method of inducing primary lung bud formation in a subject by administering a pharmaceutically effective amount of a retinoic acid receptor agonist. The invention also relates to a method of identifying an agent capable of inducing primary lung bud formation, the method comprising: (a) administering an agent to an embryo; and (b) determining primary lung bud formation of said embryo.

The invention pertains to the pharmaceutical preparation field, in particular it relates to the application of peptide and protein drug carrier and its preparation method as the drug carrier in the lung administration, according to the invention, the artificial pulmonary surfactant (APS) having drug absorption-promoting and pulmonary protective functions as a lung administered drug carrier, in particular as the carrier of protein and peptide drug to further provides a drug-APS system. The experiment proves that it can reduce alveolus surface tension, increase the lung compliance, stabilize the intra-alveolar pressure, promote the drug absorption administered from the lungs, and decreases the damage to lungs as the carrier of peptide and protein drug.

The invention discloses an endovenous oxygen transporting device and an oxygen transporting method. The oxygen transporting device comprises a vein oxygen catheter which is inserted in a vein, and a control device which is connected to the end, extending out the vein, of the vein oxygen catheter, wherein by virtue of the control device, an oxygen concentration supplied into the vein oxygen catheter can be precisely controlled. Oxygen is transported to the vein by virtue of the vein oxygen catheter which is inserted in the vein, and the oxygen, bypassing alveolus pulmonis having diffusion dysfunction, directly enters blood and oxygenates with hemoglobin, so as to better replace a lung in the case that lung failure occurs or an oxygenating effect cannot be developed temporarily; in comparison with a membrane oxygenator, an oxygen-carrying substitute or a liquid oxygen filling method, the device is simple in structure, convenient to use and capable of preventing in vitro drainage of the blood, so that various possible infections are avoided; and the device is high in blood-carrying-oxygen content and relatively good in stability.

The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains “swine” 2009 HI N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg / ml) alone or combined with or without other antivirals, a perfluorocarbon emulsion and anti-inflammatory / anti-oxidants. Where applicable, the perfluorocarbon emulsion may dissolve these agents enabling a depot effect and possible protracted delivery. In addition, perfluorocarbon emulsions have the possible added benefit of oxygen carrying capacity and alveolar nitric oxide sequestration, which may reduce peroxynitrite formation and decrease Influenza severity.

The invention discloses a probiotic composition as well as a preparation and application of the probiotic composition. The probiotic composition comprises VSL#3, lactobacillus rhamnosus M9 and lactobacillus plantarum P-8 which are mixed in an equal ratio of 1:1:1. The probiotic composition is applied to preparation of a drug for treating or preventing pneumonia, particularly pneumonia caused by respiratory syncytial virus (RSV) infection and infantile bronchopneumonia caused by RSV infection. The probiotic composition can relieve change of lung tissue inflammatory pathologic structures causedby RSV infection and inhibit virus infection process of RSV infection, activate TLR3 and RIG-1 signal pathways in alveolar macrophages to promote production of IFN-beta to inhibit expression of lung inflammation factors, and regulate lung florae and intestinal florae to relieve RSV infection.

The invention is based on the finding that Airway Basal Cells (ABCs) play a key role in the pathobiology of various lung diseases. The invention therefore provides approaches for the treatment and prevention of lung diseases such as fibrotic disorders, pre stages of fibrosis, Chronic Obstructive Lung Diseases (COPD) or other lung disorders. Diseases treatable with the means and methods of the invention are characterized by a cellular remodelling in the alveolar compartment of the lung. Furthermore, the invention provides screening approaches to identify compounds suitable for the treatment of lung diseases.

The invention relates to the application of a phycocyanin peptide in the preparation of anti-pulmonary fibrosis medicine, the amino acid sequence of which is PGSSVAVGVGKMKEAALAIV. Phycocyanin peptide can significantly improve the degree of fibrosis in pulmonary fibrosis model mice, protect the alveolar structure, reduce the inflammatory response in the fibrosis process, and reduce the collagen deposition in lung tissue. The results of in vitro experiments demonstrated that phycocyanin peptides could significantly down-regulate the collagen expression and epithelial-mesenchymal transition of human lung adenocarcinoma basal epithelial cells A549 induced by TGFβ1; Transformation of fibroblasts. Both in vivo and in vitro experimental results prove that phycocyanin peptide has significant anti-pulmonary fibrosis efficacy, and has the prospect of being used as a drug for treating or improving pulmonary fibrosis.

The invention relates to a medical apparatus, in particular to a radiofrequency ablation volume reduction electrode capable of leading out waste gas in the liver. The radiofrequency ablation volume reduction electrode comprises a radiofrequency electrode tip, a temperature measurement resistor and a liver waste gas draw-out assembly. The radiofrequency electrode tip is connected with a radiofrequency transmission hole arranged in an outer pipe to give out a radiofrequency current, and is used for conducting radiofrequency ablation on lesion tissue of alveolus pulmonis. The temperature measurement resistor is connected with a temperature measurement resistor cable and used for collecting the temperature of an ablation area and regulating the temperature released by a radiofrequency electrode. The liver waste gas draw-out assembly comprises a gas draw-out hole and a gas draw-out passageway connected with the gas draw-out hole, and is used for drawing out waste gas in the liver. The radiofrequency ablation volume reduction electrode can conduct radiofrequency ablation treatment on the lesion tissue of the alveolus pulmonis and can meanwhile draw out a large amount of gas detained in the alveolus pulmonis which loses the function, and therefore the aims of reducing the volume of the liver and treating pulmonary emphysema are achieved.

The present invention features compositions and methods for treating emphysema by reducing the amount of force the fibers in the lung (e.g., the collagen and elastin fibers in the walls of the alveoli) must bear. More particularly, in one embodiment, the invention features a pharmaceutically acceptable composition comprising a lipid that, when applied to an enlarged alveolus (e.g., an alveolus having a diameter substantially larger than (e.g., 5, 10, 20, 50 or 100 % or more than) the average alveoli in a healthy patient (i.e., a patient with no discernable lung disease), exerts a surface tension within the alveolus that substantially reduces the stress on fibers within the alveolus when inflated by a normal inspiration. The composition can display a gamma* of about 30 to about 70 dynes / cm.

The invention discloses an siRNA for silencing the expression of a Rongchang pig CD14. Firstly, a porcine alveolar macrophage of a CD14-enhanced green fluorescent protein (EGFP) fusion protein for stably expressing a Rongchang pig CD14 gene is established; next, four siRNAs having different loci and targeting the CD 14 gene are synthesized; then, the four siRNAs are transfected into a CD14-EGFP stable cell line by applying an efficient transfection reagent; and finally, the siRNAs capable of efficiently inhibiting the expression of the Rongchang pig CD14 gene are screened, namely the siRNAs inan article 3 (669) are capable of obviously inhibiting the expression of the Rongchang pig CD14 gene, and therefore, a theoretical basis is provided for researches related to inflammatory diseases caused by treating endotoxin shock, endoxemia and gram-negative bacteria by targeting the Rongchang pig CD14 gene.

The invention discloses a lung benefiting pill with 25 ingredients having the function of being homology of medicine and food. The composition of the lung benefiting pill comprises sea buckthorn, radix pseudostellariae, polyporus umbellatus, platycodon grandiflorum, stir-baked rhizoma dioscoreae, milk steamed poria cocos, longan aril, north astragalus, baked perilla seed, baked semen raphani, baked semen brassicae, radix glehniae, radix salviae miltiorrhizae, spina date seed, gecko tails, cordyceps sinensis, almonds, fructus schisandrae, linden honey, salted alisma orientalis, atractylodes macrocephala koidz baked with bran, angelica sinensis, milk steamed polygonatum kingianum, radix ophiopogonis, raw lily and the like. The lung benefiting pill is advantageous to guarantee normal ventilation of alveolus pulmonis and relieves organism anaerobic condition. Due to the fact that the permeability of lung blood capillary is improved, gas exchange is facilitated, and the symptoms of dyspnea and coughing with expectoration are relieved. Weak people with dyspnea and chronic cough generally has the abnormal phenomenon of hemorheology, synchronic treating of phlegm and blood stasis can solve the root cause of sputum and the root cause of blood stasis, bronchospasm can be relieved, discharging of sputum is promoted, cohesive force of red blood cells can be relieved, the blood viscosity is lowered, the hyperviscosity of the weak patients with dyspnea and chronic cough can be relieved, the cardio-pulmonary function of the patients can be improved, and therefore, the lung benefiting pill has good effect on treatment of the patients of this kind.

The invention discloses a probiotic composition and its preparation and application, comprising VSL#3, Lactobacillus rhamnosus M9 and Lactobacillus plantarum P‑8; the VSL#3, rhamnosus Saccharobacillus M9 and Lactobacillus plantarum P‑8 were mixed in an equal ratio of 1:1:1. The application of the probiotic composition in the preparation of medicines for treating or preventing pneumonia, especially pneumonia caused by respiratory syncytial virus infection, especially infant bronchopneumonia caused by respiratory syncytial virus infection. The probiotic composition of the present invention can alleviate the change of the inflammatory pathological structure of the lung tissue caused by RSV infection, and can inhibit the virus infection process of RSV infection; it can activate TLR3 and RIG-1 signaling pathways in alveolar macrophages to promote IFN-1 The production of β can inhibit the expression of lung inflammatory factors; it can regulate the lung flora and intestinal flora to relieve RSV virus infection.

The invention relates to a preparation for treating porcine bacterial respiratory diseases and a preparation method thereof. The preparation is used for treating porcine bacterial respiratory diseases, and the medicinal ingredients are composed of cefquinome sulfate and total saponins of Panax notoginseng. The present invention also relates to an injection for treating porcine bacterial respiratory diseases. oxime meter. In the present invention, for the first time, the preparation of cefquinoxime sulfate and total saponins of Panax notoginseng for the treatment of porcine bacterial respiratory diseases is prepared in a reasonable ratio. At the same time, it can also play an anti-fibrosis effect, inhibit the fibrinous exudation of the lungs in bacterial pig respiratory diseases, and effectively relieve the symptoms of dyspnea in a timely manner.

The invention relates to a method for screening early-stage lung tumor in an assisting mode through bronchoalveolar lavage fluid. Prior-art constraints of conventional lung outside sampling specimens and operation sampling lung specimens are broken through, normal saline is poured into the lung of a patient through a fiber bronchoscope and drawn out to form the bronchoalveolar lavage fluid, M2-PK monoclonal antibodies and second M2-PK antibodies are added, and the concentration of M2-PK in the bronchoalveolar lavage fluid is measured with the enzyme-linked immunosorbent assay method and compared with a critical value 18.68 U / ml; as the fiber bronchoscope can go deep into the lung of the patient, the bronchoalveolar lavage fluid is formed in the mode that alveolus pulmonis of the patient is directly washed and comprises alveolus pulmonis secreta, the lesion characteristics of the lung of the patient can be most reflected, the bronchoalveolar lavage fluid serves as an assistant judgment basis of the early-stage lung tumor, screening of the early-stage lung tumor is more accurate, and in addition, operation is not required, trauma is not generated, the method is safer and more reliable, and cost is also low.

The invention relates to a medical apparatus, in particular to a radiofrequency ablation volume reduction electrode capable of leading out waste gas in the liver. The radiofrequency ablation volume reduction electrode comprises a radiofrequency electrode tip, a temperature measurement resistor and a liver waste gas draw-out assembly. The radiofrequency electrode tip is connected with a radiofrequency transmission hole arranged in an outer pipe to give out a radiofrequency current, and is used for conducting radiofrequency ablation on lesion tissue of alveolus pulmonis. The temperature measurement resistor is connected with a temperature measurement resistor cable and used for collecting the temperature of an ablation area and regulating the temperature released by a radiofrequency electrode. The liver waste gas draw-out assembly comprises a gas draw-out hole and a gas draw-out passageway connected with the gas draw-out hole, and is used for drawing out waste gas in the liver. The radiofrequency ablation volume reduction electrode can conduct radiofrequency ablation treatment on the lesion tissue of the alveolus pulmonis and can meanwhile draw out a large amount of gas detained in the alveolus pulmonis which loses the function, and therefore the aims of reducing the volume of the liver and treating pulmonary emphysema are achieved.

The invention discloses an application of total flavonoids of astragalus in preparing pharmaceutical for preventing and treating acute radiation pneumonitis. The total flavonoids of astragalus contains various medicinal compositions, has prevention and treatment effects on the acute radiation pneumonitis, and can obviously alleviate lung tissue inflammatory lesion, and relieve incrassation and hyperemia of alveolar wall and alveolus pulmonis clearances, and has obvious effects.

The invention discloses a tissue engineering lung tissue and a construction method thereof, belonging to the field of tissue engineering and regenerative medicine. The tissue engineering lung tissue is obtained with the following construction method: (1) preparing lung cell suspension; (2) preparing sodium alginate-polylysine-alginate microcapsules; (3) compounding cells with holder material, andcultivating cell and holder composite. The invention adopts sodium alginate-polylysine-alginate microcapsules and combines liquid state I type collagen with Matrigel matrigel to serve as the holder of tissue engineering lungs; the holder system can effectively accelerate the formation of the alveolus pulmonis type structure to realize the exchange of air and nutritive materials, so that the invention has important significance for clinically applying tissue engineering lung tissues to treat patients with lung diseases in the future. The construction method of the invention has simple technology and moderate application condition.

The invention discloses application of Baitouweng decoction in preparation of a medicine for treating pneumonia, and belongs to the technical field of biological medicines. The Baitouweng decoction comprises the following raw materials in parts by weight of 2 parts of radix pulsatillae, 3 parts of cortex phellodendri, 3 parts of coptis chinensis and 3 parts of cortex fraxini. The Baitouweng decoction disclosed by the invention can maintain the integrity of alveolar-vascular barrier, relieve pulmonary edema and cell injury, inhibit pneumonia inflammatory response, inhibit cell apoptosis and regulate and control a TLR4 / NF-kappa B signal channel, is used for preparing the medicine for treating the pneumonia, and has a remarkable curative effect.

The invention relates to the composition and preparation method of a traditional Chinese medicine composition and its application in the preparation of anti-pulmonary fibrosis medicine. The composition is composed of astragalus, codonopsis radix, radices japonicus, schisandra chinensis, panax notoginseng, zhebei, anemarrhena anemarrhena and licorice. The composition can regulate the expression of short-chain non-coding RNAs (miRNAs) and long-chain non-coding RNAs (lncRNA), has the effect of protecting alveolar epithelial cells, interfering with the activity of myofibroblasts, and then inhibiting the process of pulmonary fibrosis, therefore The composition is expected to be well applied in the preparation of medicines for treating pulmonary fibrosis.